CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Elective Cancer SurgeryWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2230 Serologic SARS-CoV-2 screening Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis: an International, Multicentre, Observational Cohort Study (CovidSurg-Cancer)

CovidSurg-Cancer is an international, multicentre, observational cohort study designed to evaluate the 30-day COVID-19 infection rates in elective cancer surgery during the COVID-19 pandemic. Centres can elect to include one or more cancer types in the study, in any combination, depending on local expertise and capacity. During the pilot study, investigators should enrol patients with confirmed diagnoses of: - Colorectal cancer - Oesophagogastric cancer As a rapid response study to the COVID-19 pandemic, included cancer types will evolve throughout the course of the CovidSurg-Cancer study period, for example, to include breast, liver, pancreatic, gynaecological, urological cancers, or sarcomas.

NCT04384926 COVID-19 Coronavirus Cancer Surgery Procedure: Elective Cancer Surgery
MeSH:Coronavirus Infections

Primary Outcomes

Description: Frequency of COVID-19 infection within 30 days

Measure: 30-day postoperative COVID-19 infection rate

Time: 30 days

Secondary Outcomes

Description: Number of deaths at 30-days post surgery

Measure: 30-day postoperative mortality rate

Time: 30-days

Description: Critical care utilisation in high-risk cancer surgery patients

Measure: Postoperative critical care utilisation rate in high-risk cancer surgery patients.

Time: 30-days

Description: Number of patients with a delay of more than 4 weeks from the decision taken for surgery to the date of surgery

Measure: Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery

Time: More than 4 weeks from decision date

Description: Number of non-operated patients with progression to incurable disease by 3-months after decision for surgery

Measure: Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery

Time: Up to 3-months


No related HPO nodes (Using clinical trials)